Search

Your search keyword '"Jiang, Yixing"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Jiang, Yixing" Remove constraint Author: "Jiang, Yixing"
268 results on '"Jiang, Yixing"'

Search Results

1. Many-Shot In-Context Learning in Multimodal Foundation Models

2. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

4. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma

5. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

6. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

9. Evaluating General Vision-Language Models for Clinical Medicine

11. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

13. Correction: From 2 dimensions to 3rd dimension: Quantitative prediction of anterior chamber depth from anterior segment photographs via deep-learning

16. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

17. Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.

18. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial

21. Supplementary Tables 1-3 from A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent

22. Supplementary Tables and Figure from A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent

23. From 2 dimensions to 3rd dimension: Quantitative prediction of anterior chamber depth from anterior segment photographs via deep-learning

24. A phase II study of atezolizumab (ATEZO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+/- BEAT.

26. Phase I study of veliparib in combination with gemcitabine

28. Fusion power supply advances by the J-TEXT engineering team

30. American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma

32. An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC).

33. Design and Implement of Web Based SCADA System for HUST Field-Reversed Configuration Device

34. A Major Update of Web Based Development Toolkit for Control System of Large-Scale Physics Experiment Device

39. A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements

48. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).

Catalog

Books, media, physical & digital resources